62 results
Page 3 of 4
8-K
EX-99.3
umfnb9e9xbyk
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
yatrzrfpgof4qgb
6 Jan 20
Prospectus supplement for primary offering
4:42pm
S-3ASR
nsi dp6s2cmp5m
6 Jan 20
Automatic shelf registration
4:02pm
8-K
EX-99.1
f063o wehi
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
UPLOAD
3t1jb98438u39
10 Sep 19
Letter from SEC
12:00am
8-K
EX-1.1
jxvp42gdf9z0w89n
6 Mar 15
Entry into a Material Definitive Agreement
12:00am
424B3
4ho xa1l2s4zdmdayov
16 May 14
Prospectus supplement
12:00am
424B3
c9g cwrpgk7pt
4 Apr 14
Prospectus supplement
12:00am
424B1
s39gjbn5oz
31 Jan 14
Prospectus with pricing info
12:00am
424B3
xam3evry
10 Jan 14
Prospectus supplement
12:00am
8-K
col7cyefw7x7npwfl
10 Jan 14
Departure of Directors or Certain Officers
12:00am
424B3
kkcpctk ihnrhgle
19 Dec 13
Prospectus supplement
12:00am